EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature

Willemijn A M Schonck, Erik S G Stroes, G Kees Hovingh, Laurens F Reeskamp

Drugs · 2024-02 · 84 (2) · 165-178

DOI: 10.1007/s40265-024-01995-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 25.01.2024. Verfasst von Willemijn A M Schonck und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Anticholesteremic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally associated with atherosclerotic cardiovascular disease (ASCVD), and statins that lower LDL-C have been the cornerstone of ASCVD prevention for decades. However, guideline-recommended LDL-C targets are not achieved in about 60% of statin users. Proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted therapy effectively lowers LDL-C levels and has been shown to reduce ASCVD risk. A growing body of scientific and clinical evidence shows that PCSK9-targeted therapy offers an excellent safety and tolerability profile with a low incidence of side effects in the short term. In this review, we present and discuss the current clinical and scientific evidence pertaining to the long-term efficacy and tolerability of PCSK9-targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtherosclerosisAnticholesteremic AgentsHumansProprotein Convertase 9Cholesterol, LDL

Substanzen

PCSK9 protein, humanProprotein Convertase 9Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
  • Global Chief Medical Office, Novo Nordisk, Copenhagen, Denmark.
  • Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. l.f.reeskamp@amsterdamumc.nl.

Zitieren

APA

Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024). Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs, 84(2), 165-178. https://doi.org/10.1007/s40265-024-01995-9

Vancouver

Schonck WAM, Stroes ESG, Hovingh GK, Reeskamp LF. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs. 2024;84(2):165-178. doi:10.1007/s40265-024-01995-9

BibTeX
@article{Schonck2024,
  author = {Schonck, Willemijn A M and Stroes, Erik S G and Hovingh, G Kees and Reeskamp, Laurens F},
  title = {Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature},
  journal = {Drugs},
  year = {2024},
  volume = {84},
  number = {2},
  pages = {165--178},
  doi = {10.1007/s40265-024-01995-9}
}
Kostenlos starten →